p-p68 inhibitor RX-5902

Drug Overview

p-p68 inhibitor RX-5902 (brand name Supinoxin) is an investigational, first-in-class, orally bioavailable small molecule designed to target and inhibit phosphorylated p68 (p-p68). It is a highly selective agent that disrupts the function of the p68 RNA helicase, a protein that is frequently overexpressed and abnormally modified in a wide range of aggressive human cancers.

In the clinical landscape of March 2026, RX-5902 represents a novel approach to “transcriptional oncology.” While many drugs target receptors on the cell surface, RX-5902 penetrates deep into the cell to address the “master controllers” of gene expression. The p68 protein (DDX5) is a member of the DEAD-box family of RNA helicases, which are essential for processing genetic information. However, in cancer cells, p68 becomes “hyper-phosphorylated” by an enzyme called Y593, a process that transforms it from a normal cellular worker into a driver of tumor growth and metastasis. By binding specifically to this phosphorylated version, RX-5902 stops the cancer cell from being able to read and execute the instructions for spreading throughout the body. Developed by Rexahn Pharmaceuticals (now part of Ocuphire/Biosight programs), RX-5902 has shown significant potential in treating “triple-negative” and “chemo-resistant” tumors that have otherwise run out of options.

• Generic Name: p-p68 inhibitor RX-5902.
• Brand Name: Supinoxin.
• Code Name: RX-5902.
• Drug Class: RNA Helicase Inhibitor; Transcriptional Modulator.
• Mechanism: Selective binding to and inhibition of phosphorylated p68 (p-p68).
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, RX-5902 is not FDA-approved. It has been granted Orphan Drug Designation for pancreatic cancer and is currently undergoing Phase 1 and Phase 2 clinical evaluation.

What Is It and How Does It Work? (Mechanism of Action)

RX-5902 works by “jamming” the machinery the cancer cell uses to activate its survival and growth genes.

1. The Role of p68 RNA Helicase

In a healthy cell, the p68 protein helps with RNA splicing and the transition of information from DNA to proteins.

• The Oncogenic Switch: In many cancers, a mutation or signaling error causes p68 to be phosphorylated at the Y593 site. This “p-p68” version detaches from its normal duties and enters the nucleus, where it acts as a powerful “co-activator” for genes that drive cancer.

2. Inhibiting the Master Controller

RX-5902 is designed to seek out and bind specifically to this p-p68 variant.

• Blocking the Interaction: By binding to p-p68, RX-5902 prevents it from interacting with other critical proteins, such as  β-catenin and YAP1.
• Silencing the “Wnt” Pathway: The interaction between p-p68 and β-catenin is essential for the “Wnt/ β-catenin” signaling pathway, which is one of the primary ways cancer cells become “immortal” and resist chemotherapy. RX-5902 effectively “mutes” this pathway.

3. Preventing the EMT (Metastasis)

One of the most dangerous traits of cancer is the “Epithelial-to-Mesenchymal Transition” (EMT). This is the process where a tumor cell transforms into a “migratory” cell that can enter the bloodstream.

• The Brake: Research has shown that p-p68 is a major driver of the EMT. By inhibiting p-p68, RX-5902 acts as a “metastasis brake,” keeping the cancer cells locked in their original location where they are easier to treat with surgery or radiation.

Clinical Indications and Research Status (2026)

In 2026, RX-5902 is being prioritized for cancers that are notoriously difficult to treat due to their “plasticity” and resistance:

• Triple-Negative Breast Cancer (TNBC): TNBC often lacks the receptors that other drugs target. RX-5902 is being studied for its ability to target the p-p68 pathway, which is highly active in TNBC stem cells.
• Pancreatic Adenocarcinoma: Because RX-5902 has Orphan Drug Designation in this area, trials are focusing on whether the drug can penetrate the dense, “armored” shell of pancreatic tumors to stop them from spreading to the liver.
• Ovarian Cancer: Evaluated in patients who have become resistant to platinum-based chemotherapy. RX-5902 may “re-sensitize” these tumors by blocking the survival signals mediated by p-p68.
• Advanced Solid Tumors: Investigated in “basket trials” for any advanced cancer where p-p68 overexpression is confirmed via biopsy.

Dosage and Administration Protocols

As an investigational agent, RX-5902 dosing is strictly managed within clinical trial protocols (such as the RX-5902-P1 study).

Clinical Efficacy and Research Results (2024–2026)

Recent data from Phase 1/2 dose-expansion studies have highlighted the drug’s activity in late-stage disease:

• Disease Stabilization: In a 2025 update for patients with refractory TNBC, RX-5902 achieved a Disease Control Rate (DCR) of approximately 40%, with some patients remaining on the drug for over 9 months.
• Metastatic Reduction: Pre-clinical and early clinical observations in 2026 suggest that patients on RX-5902 show a significant reduction in the formation of new metastatic lesions, supporting the “metastasis brake” theory.
• Synergy with Taxanes: Research confirms that RX-5902 works significantly better when combined with Abraxane (nab-paclitaxel), as the two drugs attack the cancer cell’s structure and its genetic “brain” simultaneously.

Safety Profile and Side Effects

RX-5902 has demonstrated a generally favorable safety profile, particularly when compared to the harsh side effects of standard chemotherapy.

Common Side Effects (>20%):

• Gastrointestinal: Mild nausea, vomiting, and diarrhea.
• Fatigue: General systemic tiredness, usually most noticeable in the first two weeks of treatment.
• Decreased Appetite: Often linked to the GI effects.

Serious Risks:

• Hematologic: While rarer than with chemo, some patients experience a drop in platelets (thrombocytopenia) or white blood cells.
• Liver Enzyme Elevation: Periodic testing of ALT and AST is required to ensure the liver is processing the drug safely.
• Electrolyte Imbalance: Low levels of magnesium or potassium have been noted in a small subset of patients.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, RX-5902 is being used to study “Cancer Stem Cell Exhaustion.” Researchers are investigating how p-p68 inhibition can force a dormant cancer stem cell to “wake up” and become vulnerable to treatment. In 2026, there is also intense focus on “Immune-Evasion,” where scientists are looking at how RX-5902-induced changes in the tumor’s genetic expression can make it “visible” again to the patient’s own T-cells, potentially paving the way for combinations with immunotherapy.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• p-p68 Biomarker Test: Many trials require a biopsy to confirm that the patient’s tumor overexpresses the phosphorylated p68 target.
• Baseline Blood Work: Comprehensive monitoring of bone marrow and liver function.

“Do’s and Don’ts” List:

• DO keep a “symptom diary” for the first month; recording your fatigue and GI levels helps your oncologist adjust your dose for maximum comfort.
• DO take the capsule with a full glass of water and avoid eating for at least one hour before and after the dose.
• DON’T ignore a sudden “skin rash” or “persistent fever”; while rare, these could indicate a sensitive reaction to the drug.
• DON’T start any new “herbal supplements” (like Grapefruit seed extract) without consulting your pharmacist, as they can change how RX-5902 is absorbed.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. RX-5902 (Supinoxin) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis and clinical trial eligibility.